MIRA
INFORM REPORT
|
Report Date : |
27.09.2012 |
IDENTIFICATION DETAILS
|
Name : |
UCB PHARMA |
|
|
|
|
Registered Office : |
All?e de la Recherche 60, Bruxelles, 1070 |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Year of Establishment : |
1968 |
|
|
|
|
Com. Reg. No.: |
403096168 |
|
|
|
|
Legal Form : |
Private Subsidiary Company |
|
|
|
|
Line of Business : |
Manufacturer of pharmaceuticals focusing on severe diseases in two therapeutic areas: CNS and immunology |
|
|
|
|
No. of Employees : |
1832 employees |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
Belgium |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
belgium - ECONOMIC OVERVIEW
This modern, open, and private-enterprise-based economy has capitalized
on its central geographic location, highly developed transport network, and
diversified industrial and commercial base. Industry is concentrated mainly in
the more heavily-populated region of Flanders in the north. With few natural
resources, Belgium imports substantial quantities of raw materials and exports
a large volume of manufactures, making its economy vulnerable to volatility in
world markets. Roughly three-quarters of Belgium's trade is with other EU
countries, and Belgium has benefited most from its proximity to Germany. In
2011 Belgian GDP grew by 2.0%, the unemployment rate decreased slightly to 7.7%
from 8.3% the previous year, and the government reduced the budget deficit from
a peak of 6% of GDP in 2009 to 4.2% in 2011. Despite the relative improvement
in Belgium's budget deficit, public debt hovers near 100% of GDP, a factor that
has contributed to investor perceptions that the country is increasingly
vulnerable to spillover from the euro-zone crisis. Belgian banks were severely
affected by the international financial crisis in 2008 with three major banks
receiving capital injections from the government, and the nationalization of
the Belgian arm of a Franco-Belgian bank. An ageing population and rising
social expenditures are mid- to long-term challenges to public finances.
|
Source : CIA |
Company name & address
Ucb Pharma
All?e de la Recherche 60
Bruxelles, 1070
Belgium
Tel: 02 559 99 99
Fax: 02 559 99 00
Web: www.ucb.be
Synthesis
Employees: 1,832
Company Type: Private Subsidiary
Corporate Family: 85
Companies
Ultimate Parent: UCB SA
Incorporation Date: 1968
Financials in: USD
(Millions)
Fiscal Year End: 31-Dec-2011
Reporting Currency: Euro
Annual Sales: 1,499.2 1
Total Assets: 6,049.3
Business Description
Manufacture of pharmaceuticals focusing on severe diseases in two
therapeutic areas: CNS and immunology
Industry
Industry Biotechnology and Drugs
ANZSIC 2006: 1841 - Human
Pharmaceutical and Medicinal Product Manufacturing
NACE 2002: 2442 - Manufacture
of pharmaceutical preparations
NAICS 2002: 325412 -
Pharmaceutical Preparation Manufacturing
UK SIC 2003: 24421 -
Manufacture of medicaments
UK SIC 2007: 2120 - Manufacture
of pharmaceutical preparations
US SIC 1987: 2834 -
Pharmaceutical Preparations
Key Executives
|
Name |
Title |
|
Jean Christophe Martin Patrick M Donck |
Everyday management responsible |
|
Frederic Roch Doliveux |
Administrator |
|
Jean Jacques Fossion |
Representative/Auditor |
|
Bernard Maurice Gabriels |
Representative/Auditor |
|
Allen E Norris |
Agent, Ad hoc Agent |
news
|
Title |
Date |
|
Nodality, Inc. Appoints Laura Brege as Chief
Executive Officer |
24-Sep-2012 |
|
Patent Application Titled
"Therapeutic Combination for Painful Medical Conditions" Under
Review |
19-Sep-2012 |
|
Change in Biotie management |
17-Sep-2012 |
|
New Biotie shares and increase of share
capital registered with the Finnish Trade Register Hugin (English) (463
Words) |
17-Sep-2012 |
|
A listing prospectus concerning listing of
new shares in Biotie has been published |
7-Sep-2012 |
Registered No.(VAT): 403096168
1 - Profit & Loss Item Exchange Rate: USD 1 = EUR 0.7191895
2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.770327
Corporate Overview
Location
All?e de la Recherche 60
Bruxelles, 1070
Belgium
Tel: 02 559 99 99
Fax: 02 559 99 00
Web: www.ucb.be
Sales EUR(mil): 1,078.2
Assets EUR(mil): 4,659.9
Employees: 1,832
Fiscal Year End: 31-Dec-2011
Industry: Biotechnology and Drugs
Incorporation Date: 1968
Company Type: Private
Subsidiary
Quoted Status: Not
Quoted
Registered No.(VAT): 403096168
Everyday management
responsible: Benoit
Stevens
Contents
Industry Codes
Business Description
Financial Data
Subsidiaries
Industry Codes
ANZSIC 2006 Codes:
1841 - Human Pharmaceutical and Medicinal Product Manufacturing
NACE 2002 Codes:
2442 - Manufacture of pharmaceutical preparations
NAICS 2002 Codes:
325412 - Pharmaceutical Preparation Manufacturing
US SIC 1987:
2834 - Pharmaceutical Preparations
UK SIC 2003:
24421 - Manufacture of medicaments
UK SIC 2007:
2120 - Manufacture of pharmaceutical preparations
Business
Description
Wholesale of pharmaceutical goods
More Business
Descriptions
Manufacture of pharmaceuticals focusing on severe diseases in two
therapeutic areas: CNS and immunology
Provider of Pharmaceuticals
Pharmaceutical and Medicine Manufacturing
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Corporate
Family |
Corporate
Structure News: |
|
|
UCB SA |
|
Ucb Pharma |
|
|
|
|
|
Company Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
Parent |
Anderlecht |
Belgium |
Biotechnology and Drugs |
4,513.4 |
8,500 |
|
|
Subsidiary |
Bruxelles |
Belgium |
Biotechnology and Drugs |
1,499.2 |
1,832 |
|
|
Subsidiary |
Brussels |
Belgium |
Biotechnology and Drugs |
|
500 |
|
|
Subsidiary |
Bruxelles |
Belgium |
Business Services |
0.0 |
5 |
|
|
Subsidiary |
Bruxelles |
Belgium |
Investment Services |
0.0 |
|
|
|
Subsidiary |
Monheim Am Rhein, Nordrhein-Westfalen |
Germany |
Biotechnology and Drugs |
729.6 |
650 |
|
|
Subsidiary |
Monheim |
Germany |
Biotechnology and Drugs |
353.7 |
465 |
|
|
Subsidiary |
Shannon |
Ireland |
Biotechnology and Drugs |
107.9 |
126 |
|
|
Subsidiary |
Rochester, NY |
United States |
Biotechnology and Drugs |
128.8 |
500 |
|
|
Subsidiary |
Bruxelles |
Belgium |
Containers and Packaging |
316.5 |
455 |
|
|
Subsidiary |
Mumbai, Maharashtra |
India |
Biotechnology and Drugs |
|
450 |
|
|
Subsidiary |
Slough |
United Kingdom |
Business Services |
55.0 |
414 |
|
|
Subsidiary |
Slough |
United Kingdom |
Commercial Banks |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Commercial Banks |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Business Services |
|
|
|
|
Subsidiary |
Seymour, IN |
United States |
Biotechnology and Drugs |
94.3 |
400 |
|
|
Subsidiary |
Bulle |
Switzerland |
Biotechnology and Drugs |
|
375 |
|
|
Subsidiary |
Smyrna, GA |
United States |
Miscellaneous Financial Services |
333.2 |
350 |
|
|
Branch |
Smyrna, GA |
United States |
Medical Equipment and Supplies |
96.6 |
300 |
|
|
Division |
Smyrna, GA |
United States |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Smyrna, GA |
United States |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Raleigh, NC |
United States |
Business Services |
|
350 |
|
|
Subsidiary |
Tokyo |
Japan |
Biotechnology and Drugs |
20.0 |
300 |
|
|
Subsidiary |
Brussels |
Belgium |
Biotechnology and Drugs |
|
300 |
|
|
Subsidiary |
Colombes |
France |
Biotechnology and Drugs |
254.8 |
224 |
|
|
Subsidiary |
Monheim Am Rhein, Nordrhein-Westfalen |
Germany |
Biotechnology and Drugs |
93.5 |
210 |
|
|
Subsidiary |
Bulle |
Switzerland |
Biotechnology and Drugs |
2,525.5 |
141 |
|
|
Subsidiary |
Milano, Milano |
Italy |
Chemical Manufacturing |
234.1 |
138 |
|
|
Subsidiary |
Warsaw |
Poland |
Biotechnology and Drugs |
|
120 |
|
|
Subsidiary |
Kuala Lumpur |
Malaysia |
Biotechnology and Drugs |
|
100 |
|
|
Subsidiary |
Athens |
Greece |
Biotechnology and Drugs |
|
100 |
|
|
Subsidiary |
Shanghai |
China |
Personal and Household Products |
|
88 |
|
|
Subsidiary |
Craigieburn, VIC |
Australia |
Fabricated Plastic and Rubber |
75.0 |
75 |
|
|
Subsidiary |
Barueri, Sao Paulo |
Brazil |
Medical Equipment and Supplies |
12.5 |
75 |
|
|
Subsidiary |
Prague |
Czech Republic |
Biotechnology and Drugs |
|
50 |
|
|
Subsidiary |
Budapest |
Hungary |
Personal and Household Products |
|
42 |
|
|
Subsidiary |
Seoul, Seoul |
Korea, Republic of |
Biotechnology and Drugs |
15.7 |
40 |
|
|
Subsidiary |
Osteras |
Norway |
Biotechnology and Drugs |
15.6 |
35 |
|
|
Subsidiary |
Copenhagen |
Denmark |
Biotechnology and Drugs |
0.0 |
35 |
|
|
Subsidiary |
Budapest |
Hungary |
Biotechnology and Drugs |
|
35 |
|
|
Subsidiary |
Crisnee |
Belgium |
Construction Services |
0.0 |
30 |
|
|
Subsidiary |
Espoo |
Finland |
Biotechnology and Drugs |
25.9 |
20 |
|
|
Subsidiary |
Paço de Arcos, Lisboa |
Portugal |
Biotechnology and Drugs |
25.8 |
20 |
|
|
Subsidiary |
Dublin |
Ireland |
Business Services |
12.8 |
15 |
|
|
Subsidiary |
Paco d'Arcos |
Portugal |
Biotechnology and Drugs |
0.0 |
15 |
|
|
Subsidiary |
Sint-Job-In-'t-Goor |
Belgium |
Real Estate Operations |
5.7 |
13 |
|
|
Subsidiary |
Lierneux |
Belgium |
Retail (Grocery) |
2.7 |
10 |
|
|
Subsidiary |
Oakville, ON |
Canada |
Biotechnology and Drugs |
10.7 |
6 |
|
|
Subsidiary |
Malvern, VIC |
Australia |
Biotechnology and Drugs |
6.7 |
2 |
|
|
Subsidiary |
Breda |
Netherlands |
Investment Services |
|
2 |
|
|
Subsidiary |
Monheim Am Rhein, Nordrhein-Westfalen |
Germany |
Chemicals - Plastics and Rubber |
|
205 |
|
|
Subsidiary |
Breda |
Netherlands |
Biotechnology and Drugs |
34.7 |
40 |
|
|
Subsidiary |
Vienna |
Austria |
Biotechnology and Drugs |
29.6 |
25 |
|
|
Subsidiary |
Stockholm |
Sweden |
Biotechnology and Drugs |
15.3 |
14 |
|
|
Subsidiary |
Bulle |
Switzerland |
Investment Services |
|
|
|
|
Subsidiary |
Bulle |
Switzerland |
Investment Services |
|
|
|
|
Subsidiary |
Sleidinge |
Belgium |
Oil and Gas Operations |
0.5 |
1 |
|
|
Subsidiary |
Kerpen |
Germany |
Chemical Manufacturing |
75.0 |
|
|
|
Subsidiary |
Wiesbaden |
Germany |
Chemical Manufacturing |
250.0 |
|
|
|
Subsidiary |
Warsaw |
Poland |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Luxembourg |
Luxembourg |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Paris |
France |
Business Services |
|
|
|
|
Subsidiary |
Zhuhai, Guangdong |
China |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Miguel Hidalgo |
Mexico |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Business Services |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Personal and Household Products |
|
|
|
|
UK Branch/Trading address |
Slough |
United Kingdom |
Biotechnology and Drugs |
|
117 |
|
|
Subsidiary |
Slough |
United Kingdom |
Business Services |
|
|
|
|
Subsidiary |
Wigton |
United Kingdom |
Investment Services |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Commercial Banks |
|
|
|
|
Subsidiary |
Wigton |
United Kingdom |
Miscellaneous Financial Services |
|
|
|
|
Subsidiary |
Wigton |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Sofia |
Bulgaria |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Moscow |
Russian Federation |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Business Services |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Nonclassifiable Industries |
|
35 |
|
|
Subsidiary |
Slough |
United Kingdom |
Business Services |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Business Services |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Investment Services |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Investment Services |
|
|
|
|
Subsidiary |
Slough |
United Kingdom |
Commercial Banks |
|
|
|
|
Subsidiary |
Madrid |
Spain |
Retail (Drugs) |
|
|
Executive report
|
Executives |
|
|
|
|
||||
|
Everyday management responsible |
Managing Director |
|
||||
|
|||||||
|
Everyday management responsible |
Managing Director |
|
|
|||
|
Everyday management responsible |
Managing Director |
|
|
|||
|
Administrator |
Administration Executive |
|
|
|||
|
|||||||
|
Administrator |
Administration Executive |
|
|
|||
|
|||||||
|
Administrator |
Administration Executive |
|
|
|||
|
Administrator |
Administration Executive |
|
|
|||
|
Administrator |
Administration Executive |
|
|
|||
|
Administrator |
Administration Executive |
|
|
|||
|
|||||||
|
Ad hoc Agent, Administrator, Agent |
Administration Executive |
|
|
|||
|
Representative/Auditor |
Accounting Executive |
|
|
|||
|
|||||||
|
Representative/Auditor |
Accounting Executive |
|
|
|||
|
|||||||
|
Agent, Ad hoc Agent |
Other |
|
|
|||
|
|||||||
NEWS
|
Nodality, Inc. Appoints Laura Brege as
Chief Executive Officer |
24-Sep-2012 |
|
Patent Application Titled
"Therapeutic Combination for Painful Medical Conditions" Under
Review Biotech Week (2078
Words) |
19-Sep-2012 |
|
Change in Biotie management |
17-Sep-2012 |
|
New Biotie shares and increase of share
capital registered with the Finnish Trade Register |
17-Sep-2012 |
|
A listing prospectus concerning listing of
new shares in Biotie has been published |
07-Sep-2012 |
|
Agency Reviews Patent Application Approval
Request for "Transdermal Delivery System for the Administration of
Rotigotine" |
05-Sep-2012 |
|
Patent Issued for Transdermal Delivery
System |
29-Aug-2012 |
|
Patent Issued for Transdermal Delivery
System for the Administration of Rotigotine |
29-Aug-2012 |
|
US Patent Issued to UCB Pharma on Aug. 21
for "Transdermal Delivery System for the Administration of
Rotigotine" (German Inventors) |
28-Aug-2012 |
|
US Patent Issued to UCB Pharma on Aug. 14
for "Fused Thiazole Derivatives as Kinase Inhibitors" (British,
Belgian Inventors) |
20-Aug-2012 |
ARTICLES
|
UCB Pharma GmbH Files Patent Application
for Pharmaceutical Composition Comprising Rotigotine Salts (Acid or Na),
Especially for Iontophoresis |
22-Aug-2012 |
|
UCB Pharma SA Files Patent Application for
Antibody-Guided Fragment Growth |
23-Jul-2012 |
|
UCB Implements Revitas Product Suite to
Optimize Enterprise Revenue Dynamics |
13-Jun-2012 |
|
UCB Pharma SA Files Patent Application for
Prolonged Release Formulations Comprising an 2-0x0-1- Pyrrolidine Derivate |
11-Jun-2012 |
|
UCB Pharma SA Receives Patent for Methods
for Producing Recombinant Proteins |
10-Jun-2012 |
|
United States : UCB, Inc. Adopts Revitas
Product Suite to Optimize Enterprise Revenue Dynamics |
08-Jun-2012 |
|
United States : Research deal inked
between UCB Pharma and Oxford University |
22-Mar-2012 |
|
Nektar Cashes in Cimzia, Mircera Royalties
for $124M |
01-Mar-2012 |
|
UNITED STATES : MULTI year research collaboration
between UCB PHARMA and NODALITY |
13-Feb-2012 |
|
BELGIUM,UNITED STATES : Nodality and UCB
Enter into a Multi-Year Strategic Collaboration |
11-Feb-2012 |
ANNUAL PROFIT & LOSS
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
|
Period Length |
52 Weeks |
52 Weeks |
52 Weeks |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate
(Period Average) |
0.71919 |
0.755078 |
0.719047 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Turnover |
1,499.2 |
1,530.8 |
856.6 |
|
Increase or
Decrease in Stocks of Finished Goods, and Orders in Progress |
148.6 |
-3.0 |
22.7 |
|
Immobilized
Production |
686.5 |
654.6 |
672.1 |
|
Other Operating
Income |
495.7 |
368.5 |
442.9 |
|
Operating Income |
2,829.9 |
2,551.0 |
1,994.3 |
|
Purchases |
526.5 |
279.4 |
256.6 |
|
Increase
or Decrease in Stocks |
12.9 |
16.7 |
21.1 |
|
Raw Materials,
Consumables, and Goods for Release |
539.4 |
296.1 |
277.7 |
|
Services and
Sundry Goods |
1,218.3 |
1,102.9 |
1,134.0 |
|
Remuneration,
Social Security Charges, and Pensions |
311.3 |
284.2 |
380.6 |
|
Depreciation of
and Other Amounts Written Off of Formation Expense, Intangible and Tangible Fixed
Assets |
813.6 |
760.6 |
760.5 |
|
Increase or
Decrease in Amounts Written Off Stocks, Orders, and Trade Debtors |
-4.5 |
12.1 |
-21.9 |
|
Provisions for
Liabilities and Charges |
6.5 |
-24.1 |
-105.2 |
|
Other Operating
Charges |
7.0 |
9.1 |
3.1 |
|
Operating
Charges |
2,891.5 |
2,440.9 |
2,428.9 |
|
Income From
Financial Fixed Assets |
91.8 |
291.6 |
0.1 |
|
Income From
Current Assets |
8.2 |
1.2 |
0.0 |
|
Other Financial
Income |
202.4 |
116.1 |
315.3 |
|
Financial Income |
302.4 |
408.9 |
315.4 |
|
Interest and Other
Debt Charges |
154.0 |
118.0 |
127.2 |
|
Other Financial
Charges |
82.9 |
130.8 |
160.1 |
|
Financial
Charges |
236.9 |
248.8 |
287.3 |
|
Adjustments to Depreciation
of and to Other Amounts Written Off Intangible and Tangible Fixed Assets |
21.1 |
29.2 |
24.6 |
|
Adjustments to
Amounts Written Off on Financial Fixed Assets |
- |
4.3 |
- |
|
Adjustments to Provisions
for Extraordinary Liabilities and Charges |
17.0 |
9.4 |
24.7 |
|
Gain on Disposal
of Fixed Assets |
11.6 |
- |
0.2 |
|
Other
Extraordinary Income |
2.6 |
4.5 |
173.4 |
|
Extraordinary
Income |
52.3 |
47.4 |
223.0 |
|
Depreciation of and
Other Amounts Written Off Formation Expenses, Intangible, and Tangible Fixed
Assets |
18.3 |
28.3 |
43.6 |
|
Amounts Written
Off on Financial Fixed Assets |
2.4 |
- |
4.6 |
|
Provisions for
Extraordinary Liabilities and Charges |
9.6 |
-15.3 |
35.3 |
|
Loss on Disposal
of Fixed Assets |
29.9 |
3.7 |
1.0 |
|
Other
Extraordinary Charges |
29.8 |
12.4 |
- |
|
Extraordinary
Charges |
90.1 |
29.1 |
84.5 |
|
Transfer from
Differed Taxes |
0.3 |
0.2 |
0.3 |
|
Income Taxes |
0.5 |
1.1 |
1.2 |
|
Adjustment of
Income Taxes and Write-Back of Tax Provisions |
0.1 |
- |
- |
|
Income Taxes |
0.4 |
1.1 |
1.2 |
|
Transfer from
Untaxed Reserves |
0.5 |
0.5 |
0.5 |
|
From
Capital and Share Premium Account |
- |
263.0 |
499.3 |
|
Transfers From
Capital and Reserves |
- |
263.0 |
499.3 |
|
To
the Legal Reserve |
- |
14.4 |
- |
|
Transfers to
Capital and Reserves |
- |
14.4 |
- |
|
Return
on Capital |
- |
112.6 |
- |
|
Profit to be
Distributed |
- |
112.6 |
- |
|
Employees |
1,832 |
1,758 |
1,912 |
Annual Balance
Sheet
Financials in: USD (mil)
|
|
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
|
Filed Currency |
EUR |
EUR |
EUR |
|
Exchange Rate |
0.770327 |
0.745406 |
0.696986 |
|
Consolidated |
No |
No |
No |
|
|
|
|
|
|
Intangible
Assets |
1,755.7 |
1,842.1 |
1,998.7 |
|
Land
& Buildings |
88.1 |
88.8 |
112.0 |
|
Plant,
Machinery, and Equipment |
67.4 |
72.0 |
95.4 |
|
Furniture
and Vehicles |
5.9 |
4.8 |
37.0 |
|
Leasing
and Other Similar Rights |
46.5 |
51.9 |
59.9 |
|
Assets
Under Construction and Advance Payments |
66.0 |
57.5 |
17.3 |
|
Tangible
Assets |
273.8 |
275.0 |
321.6 |
|
Participating
Interests |
2,328.6 |
2,406.5 |
2,573.8 |
|
Affiliated
Enterprises |
2,328.6 |
2,406.5 |
2,573.8 |
|
Participating
Interests |
19.3 |
22.3 |
9.7 |
|
Amounts
Receivable |
3.2 |
1.7 |
- |
|
Other
Enterprises Linked by Participating Interests |
22.5 |
23.9 |
9.7 |
|
Amounts
Receivable and Cash Guarantees |
0.2 |
0.1 |
0.1 |
|
Other
Capital Assets |
0.2 |
0.1 |
0.1 |
|
Capital
Assets |
2,351.4 |
2,430.5 |
2,583.6 |
|
Fixed Assets |
4,380.8 |
4,547.6 |
4,903.9 |
|
Other
Amounts Receivable |
- |
- |
1.2 |
|
Amounts
Receivable After More Than One Year |
- |
- |
1.2 |
|
Raw
Materials and Consumables |
35.9 |
13.0 |
48.9 |
|
Work
in Progress |
0.8 |
1.9 |
2.7 |
|
Finished
Goods |
237.5 |
74.8 |
55.8 |
|
Goods
Purchased for Resale |
0.1 |
58.1 |
87.7 |
|
Stocks |
274.3 |
147.8 |
195.1 |
|
Inventory
and Orders in Progress |
274.3 |
147.8 |
195.1 |
|
Trade
Debtors |
358.0 |
411.5 |
358.3 |
|
Other
Amounts Receivable |
1,020.8 |
590.5 |
19.0 |
|
Amounts
Receivable Within One Year |
1,378.9 |
1,002.0 |
377.3 |
|
Liquid
Assets |
2.7 |
1.6 |
3.3 |
|
Adjustment
Accounts |
12.6 |
14.9 |
11.6 |
|
Current Assets |
1,668.5 |
1,166.3 |
588.5 |
|
Total Assets |
6,049.3 |
5,713.8 |
5,492.4 |
|
Issued
Capital |
901.5 |
931.7 |
563.9 |
|
Capital |
901.5 |
931.7 |
563.9 |
|
Legal
Reserve |
14.2 |
14.7 |
0.1 |
|
Other |
0.0 |
0.0 |
0.0 |
|
Reserves
Not Available for Distribution |
0.0 |
0.0 |
0.0 |
|
Untaxed
Reserves |
6.7 |
7.5 |
8.5 |
|
Reserves |
20.9 |
22.1 |
8.6 |
|
Pensions
and Similar Obligations |
13.8 |
18.6 |
1.0 |
|
Other
Liabilities and Charges |
112.1 |
112.5 |
192.1 |
|
Provisions
for Liabilities and Charges |
126.0 |
131.1 |
193.1 |
|
Deferred
Taxation |
3.4 |
3.7 |
4.2 |
|
Provisions
and Deferred Taxes |
129.4 |
134.8 |
197.3 |
|
Capital and
Reserves |
1,049.0 |
1,117.0 |
287.6 |
|
Other
Loans |
3,450.9 |
2,867.2 |
1,959.2 |
|
Financial
Debts |
3,450.9 |
2,867.2 |
1,959.2 |
|
Other
Amounts Payable |
19.9 |
9.5 |
14.1 |
|
Amounts
Due After More Than One Year |
3,470.8 |
2,876.6 |
1,973.3 |
|
Current
Portion of Amounts Payable After More Than One Year |
- |
- |
1.4 |
|
Credit
Institutions |
103.3 |
4.5 |
0.6 |
|
Other
Loans |
257.1 |
302.4 |
1,814.7 |
|
Financial
Debts |
360.4 |
306.9 |
1,815.4 |
|
Suppliers |
412.8 |
458.5 |
331.0 |
|
Trade
Debts |
412.8 |
458.5 |
331.0 |
|
Taxes |
6.3 |
0.0 |
0.0 |
|
Remuneration
and Social Security |
71.2 |
42.7 |
52.2 |
|
Taxes,
Wages, and Social Security |
77.5 |
42.8 |
52.2 |
|
Other
Amounts Payable |
146.2 |
141.5 |
21.8 |
|
Amounts
Payable Within One Year |
997.0 |
949.5 |
2,221.9 |
|
Adjustment
Accounts |
403.1 |
635.9 |
812.4 |
|
Creditors |
4,870.9 |
4,462.1 |
5,007.5 |
|
Total
Liabilities + Shareholders' Equity |
6,049.3 |
5,713.8 |
5,492.4 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.53.58 |
|
UK Pound |
1 |
Rs.86.60 |
|
Euro |
1 |
Rs.68.94 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.